#USA #Flagstaff #GORE #VIABAHN #VBX

W.L. Gore & Associates Introduces Lower Profile VBX Endoprosthesis

W.L. Gore & Associates, Inc. recently announced the CE mark approval for its GORE® VIABAHN® VBX balloon expandable endoprosthesis, a significant advancement in medical solutions for patients dealing with complex vascular diseases. This innovative device aims to improve treatment options by offering a lower profile that is now compatible with a 6 French (Fr) sheath, making it a versatile tool for physicians.

Enhancements in Design and Functionality

The lower profile of the VBX device has been achieved through enhancements in the deployment system, allowing a reduction of 1 Fr in most sizes without altering the stent's design. This results in greater procedural efficiency, minimal risk of complications, and improved usability. Physicians can expect enhanced performance without sacrificing the established reliability that the GORE® VIABAHN® family of stents is known for.

Professor Michele Antonello, Director of the Vascular Surgery Residency Program at the University of Padua, commented on the benefits of this new device, stating, "The new lower profile will enhance my ability to manage complex cases with 6 or 7 Fr devices, while ensuring precision and flexibility during procedures."

Clinical Significance and Study Insights

Over the years, the GORE® VIABAHN® endoprostheses have become crucial in treating various vascular diseases, with the recent data reinforcing their effectiveness. The latest results from a five-year clinical assessment indicate promising outcomes, further supporting the use of this lower profile device in complicated scenarios. Dr. Ash Patel, a vascular surgeon at Guy's & St Thomas' Hospital NHS Foundation Trust in London, adds, "With ongoing studies like GORE VBX FORWARD, which compares the VBX with bare-metal stents for complex iliac artery disease, the lower profile innovation is an exciting addition that builds on our confidence in the VBX's reliable results."

Market Availability and Continued Commitment

Since its initial release in the United States in 2017, more than 500,000 GORE® VIABAHN® VBX stents have been implanted globally. The lower profile device is set to launch in European markets in the upcoming months, showcasing Gore's dedication to continuous improvement and innovation in medical technologies, especially in partnership with healthcare providers facing challenging patient needs.

Jill Paine, Business Director for Gore's peripheral products, emphasized the company's ongoing mission: "The approval of the lower profile VBX endoprosthesis highlights our commitment to advancing medical device technology that addresses critical patient challenges. We are eager to empower physicians with this innovative tool in their treatment arsenal."

Conclusion

As W.L. Gore & Associates continues to lead in the medical devices sector, the introduction of the GORE® VIABAHN® VBX endoprosthesis serves as a testament to their ongoing efforts to enhance the effectiveness of treatments for vascular disease. For more information on this innovative product, healthcare professionals can visit goremedical.com/eu/products/vbx. Gore's longstanding legacy and dedication to improving patient outcomes remain pivotal in their operations, having implanted over 50 million devices in 45 years. Each innovation continues to reinforce their status as a leader in the medical field, dedicated to enhancing lives through technology.